Dr. Guo Liang Yu is a co-founder, Executive Director, Chairman and Chief Executive Officer of Apollomics. Dr. Yu has been one of the key management members of the Company and has been actively involved in its business, strategy and operational management since its establishment. He has over 31 years of experience in the pharmaceutical industry and academic research. He is a serial entrepreneur and has co-founded over ten startup companies in biotech and the healthcare sectors, including Immune-Onc Therapeutics, Inc. in Palo Alto, United States. During his co-founding of our Group, Dr. Yu was the executive chairman of Crown Bioscience International and he was also a venture partner with OrbiMed Asia Limited.

Dr. Yu obtained his Ph.D. degree in molecular biology from the University of California, Berkeley in the U.S. He has served important roles in numerous social organizations, including the founding president of the Chinese Biopharmaceutical Association USA. Inc. and as a board member of Ray Wu Memorial Fund. Dr. Yu is currently a member of the Board of Directors of the following companies: Immune-Onc Therapeutics, Inc., Zhejiang Innoforce Pharmaceuticals Co., and Inmagene Biopharmaceuticals.

Dr. Sanjeev Redkar is a co-founder and Director of Apollomics. He has over 26 years of scientific, managerial and executive experience in hematology and oncology drug discovery and development, especially for small-molecule drugs. Dr. Redkar previously served as President of Apollomics from 2016 until 2024. Before founding Apollomics, he was a senior vice president for product development at Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) and worked as the manager of process development and manufacturing, senior director of pharmaceutical development, vice president in charge of manufacturing and preclinical development successively at SuperGen, Inc. before its acquisition of Astex Therapeutics Limited.

Dr. Redkar received his Bachelor of Technology degree in chemical engineering from Indian Institute of Technology in India, and he holds a Master of Science degree in chemical engineering and a Ph.D. degree in chemical engineering from University of Colorado, Boulder in the United States. He also obtained a Master of Business Administration degree from St. Mary’s College of California in the United States. Dr. Redkar has authored and co-authored over 25 peer-reviewed scientific articles and co-invented 26 patents that have been issued in the United States. Dr. Redkar serves as Adjunct Faculty and as an Industrial Advisory Board Member at the T.J. Long School of Pharmacy of the University of Pacific. He also serves as a Board Member, Faculty, and Entrepreneur-in-Residence at the Jie Du Center for Entrepreneurship.

Dr. Ken Carter serves on the Apollomics Board as an independent director since March 2023. Ken has been involved in the formation and development of multiple biotechnology companies as co-founder, consultant or member of the board of directors for more than 20 years. Ken serves on several biotechnology company boards including as Chairman of Noble Life Sciences, where he is a co-founder and former CEO. Ken also co-founded and served as CEO for multiple years at Avalon Pharmaceuticals and NexImmune, both of which completed IPO listings on NASDAQ. During his tenure at Avalon, Ken oversaw development of a unique biomarker-based drug discovery and development engine, established drug discovery programs in colon, breast, pancreatic, and hematological cancers and formed partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior, he directed the gene-mapping initiative at Human Genome Sciences. Recently, Ken was a special advisor to the Maryland Governor’s Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he held an adjunct faculty appointment for 10 years. Ken holds a Bachelors degree in Biology from Abilene Christian University and a Ph.D. in Human Genetics and Cell Biology from the University of Texas Medical Branch.

Dr. Chen serves on the Apollomics Board as an independent director since March 2023. Dr. Chen has extensive experiences in therapeutics research and development, regulatory strategy, and company operation. He was the CEO and Chairman of Maxpro Capital Acquisition Corp. which merged with Apollomics in March 2023. Currently he is a managing partner at Maxpro ventures. Prior to joining Maxpro ventures, Dr. Chen held management and R&D positions at various biotech companies including SyneuRx International Inc., Meridigen, Celgene, Amcyte, and VivoRx.

Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He did his postdoctoral training in neuroscience at Caltech.

Wendy Hayes serves on the Apollomics Board as an independent director since March 2023 and brings extensive financial and business oversight experience. She is a partner at a venture capital firm based in Silicon Valley and serves on the boards of several NYSE and Nasdaq listed companies. In December 2022, Wendy completed a two-year fellowship in Advanced Leadership Initiative at Harvard University. Wendy also worked as an Inspections Leader and led inspections for the Public Company Accounting Oversight Board (PCAOB), an organization established by the U.S. Congress, overseen by the Securities and Exchange Commission (SEC). Previously, Wendy worked at various Deloitte global offices as an Audit Partner after she first joined Deloitte San Francisco in 1997. Wendy is a certified public accountant in the United States (California) and China. She is based in the US and Europe.

Wendy received her bachelor’s degree in international finance from University of International Business and Economics in 1991, and her executive MBA from Cheung Kong Graduate School of Business in 2012.

Glenn serves on the Apollomics Board as an independent director since March 2023. Glenn’s career spans more than 20 years of financial and commercial experience in the life sciences industry. Currently Glenn is the Chief Financial Officer (CFO) at Inversago. Prior to that, he was the CFO of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. He has also served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018. Additionally, Glenn served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as Executive Vice President.

Glenn received an Electronic Engineering Technology degree and a Managerial MBA in Finance from the Rutgers University Center for Management Development.

Robert Lin, MD, PhD, is a physician and researcher who has conducted dozens of multinational clinical trials and is experienced in genomics and proteomics. His extensive background in clinical medicine and basic research enables him to delve into the fundamentals of new innovations and provide thorough assessments of their clinical applications. Dr. Lin has evaluated hundreds of biotech and healthcare investments and has been involved in dozens of multi-million-dollar biotech deals. He serves as a trusted advisor on multiple committees in the Asia-Pacific region.

Dr. Lin has served as the vice director of the Internal Medicine Department at a tertiary medical center in Taiwan and as a member of the censorship committee of the AAHRPP-certified Institutional Review Board. He conducted post-doctoral research at Lawrence Berkeley Laboratory in the USA.